| Abigail Denque, | |
|
3301 Greenlawn Blvd, Round Rock, TX 78664-2529 | |
| (737) 247-1686 | |
| Not Available |
| Full Name | Abigail Denque |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3301 Greenlawn Blvd, Round Rock, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033874813 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Abigail Denque, 3001 Scofield Ridge Pkwy Apt 2312, Austin, TX 78727-6544 Ph: (425) 647-1007 | Abigail Denque, 3301 Greenlawn Blvd, Round Rock, TX 78664-2529 Ph: (737) 247-1686 |
News Archive
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ignore cancer cells.
Kessler researchers assessed moderate to severe traumatic brain injury (TBI) for frontal behavioral syndromes and cognitive function. Their finding suggest that adding the Frontal Systems Behavior Scale to neuropsychological assessment may yield useful information about the behavioral sequelae of TBI.
Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.
The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group's results for the first half 2009, published today. The full 2009 half year financial report is available on the Group's web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.
Pfizer Inc. announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration. The worldwide suspension – which is effective immediately – follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement.
› Verified 2 days ago
Stephanie Nicole Perez, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1511 Gulf Way, Round Rock, TX 78665 Phone: 512-424-8789 | |
Kathleen T. Castro, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1009 N Georgetown St, Round Rock, TX 78664 Phone: 512-244-8374 | |
Deborah Skotak, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1009 N Georgetown St, Round Rock, TX 78664 Phone: 512-255-1720 Fax: 512-244-8403 | |
Lisa Woodruff, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1009 N Georgetown St, Round Rock, TX 78664 Phone: 512-255-1720 | |
Katherine Sheets, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 4105 Teravista Club Dr, Round Rock, TX 78665 Phone: 512-310-3700 | |
Christine Marques, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1208-q North Ih-35, Round Rock, TX 78681 Phone: 512-310-7665 Fax: 512-310-9228 | |
Danya Weinheimer, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 901 Round Rock Ave, Building E, Round Rock, TX 78681 Phone: 512-341-9991 Fax: 512-341-0019 |